Alzheimer's Disease Clinical Trials in Philadelphia

Showing 161-180 of 266 trials

Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD)

NCT03088956

The objectives of the study are to; (1) estimate the change in disease -related cognitive decline over 1 year on a battery of cognitive tests administered to participants with early-stage symptomatic Behavioral Variant Frontotemporal Dementia (bvFTD) phenotypic variant; (2) identify the cognitive test or brief battery of cognitive tests which are the most sensitive to detect bvFTD progression; (3) determine the optimal schedule of administration of cognitive tests to detect bvFTD progression; (4) evaluate the relationship between cognitive tests and measures of behavior, function, caregiver's burden, quality of life (QOL); and (5) obtain blood samples for genetic and exploratory biomarkers correlations.

Frontotemporal DementiaBehavioral Variant Frontotemporal Dementia

Biogen47 participantsStarted Jan 2018

Birmingham, Alabama, United States • Los Angeles, California, United States • Boca Raton, Florida, United States +9 more locations

TERMINATEDPhase 3< 1 mile

Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo

NCT01900665

To test the idea that solanezumab will slow the cognitive decline of Alzheimer's Disease (AD) as compared with placebo in participants with mild AD.

Alzheimer's Disease

Eli Lilly and Company2,129 participantsStarted Jul 2013

Phoenix, Arizona, United States • Phoenix, Arizona, United States • Phoenix, Arizona, United States +195 more locations

Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD)

Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo

Alzheimer's Disease Trials in Other Cities

Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease

Modulation of Monocyte Activation by Atorvastatin in HIV Infection

A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease

A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab

A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease

Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)

Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease

Hand Grasping Techniques on Eliciting the Grasp Reflex in Patients With Dementia

The Use of Antipsychotics in the Program of All-inclusive Care for the Elderly (PACE)

Efficacy of 1072nm Infrared Stimulation on Executive Functioning in Dementia

Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease

Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study

AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease

A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease

Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants

A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease

Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)

Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder

Other Conditions in Philadelphia